04:25 AM EDT, 09/09/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Sunday its analysis of a phase 3 trial of its drug datopotamab deruxtecan showed a "meaningfully greater magnitude of efficacy" versus docetaxel in the treatment of patients with advanced or metastatic non-small cell lung cancer.

According to the analysis, treatment with datopotamab deruxtecan reduced the risk of disease progression or death by 25% to 48% compared with docetaxel.

The analysis was conducted using AstraZeneca's ( AZN ) QCS pathology platform that assesses digitized images of patient tissue samples and identifies proteins on and inside tumor cells.

Datopotamab deruxtecan is a treatment discovered by Japan's Daiichi Sankyo and being jointly developed by it and AstraZeneca ( AZN ).

Price: 82.68, Change: -0.37, Percent Change: -0.45